Hannah K. Lord

Dundee, SCT, GB 
Dundee, SCT, GB 

Overview

Hannah Lord practices practicing medicine in Dundee, United Kingdom.

Her clinical expertise encompasses Oligodendroglioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Spinal Tumor.

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Dundee, SCT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers
A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers
Enrollment Status: Unknown
Publish Date: August 22, 2017
Intervention Type: Drug
Study Drugs: Apatorsen, Gemcitabine, Carboplatin
Study Phase: Phase 2
View 1 Less Clinical Trial

8 Total Publications

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.
Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.
Journal: Neuro-oncology
Published: July 22, 2025

Frequently Asked Questions about Hannah K. Lord

Is Hannah K. Lord a top-rated expert for Oligodendroglioma?

MediFind is an objective health platform that identifies experts based on real-world data. Hannah K. Lord is classified as an Experienced expert for Oligodendroglioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hannah K. Lord participate in research or clinical trials?

Yes. Hannah K. Lord has published 8 articles and abstracts on conditions like Oligodendroglioma. You can view a list of Hannah K. Lord's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lord's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile